Physician profile
Michael C Smith
NPI 1285620617
$381,988.74
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $47K · 2021: $116K · 2022: $95K · 2023: $72K · 2024: $33K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $105K · Travel and Lodging: $15K · Food and Beverage: $2,354 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $105,300.00 |
| Travel and Lodging | $15,292.35 |
| Food and Beverage | $2,353.65 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $296,983.00 | 2020-2025 | Xcopri |
| Neurelis, INC. | $78,910.98 | 2020-2022 | |
| Greenwich Biosciences, INC. | $2,706.00 | 2020 | |
| Azurity Pharmaceuticals, INC. | $2,379.38 | 2022-2023 | |
| Aquestive Therapeutics, INC. | $513.41 | 2019 | |
| Acclarent, INC | $136.61 | 2020-2023 | Relieva Tract, Trudi Nav Cable, Relieva Spinplus |
| Axonics, INC. | $128.51 | 2022 | |
| Ucb, INC. | $72.77 | 2023 | |
| Forte Bio-Pharma LLC | $37.83 | 2025 | Tanlor |
| Abbott Laboratories | $28.68 | 2019 | |
| Corium, LLC | $25.12 | 2023 | Adlarity |
| Jazz Pharmaceuticals INC. | $20.45 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.71 | 2019 | |
| Biocodex, INC. | $13.55 | 2025 | |
| Livanova USA, INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.